Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 06, 2015; 84 (14 Supplement) April 21, 2015

Comparative Cognitive Effects of Lacosamide versus Carbamazepine (P3.191)

David Loring, Kimford Meador, Alan Boyd, William Byrnes, Deanne Dilley, Simon Borghs, Marc De Backer, Tyler Story, Peter Dedeken, Elizabeth Webster
First published April 8, 2015,
David Loring
2Emory University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimford Meador
3Stanford University School of Medicine Stanford CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Boyd
1CNS Vital Signs Chapel Hill NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Byrnes
5UCB Pharma Raleigh NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deanne Dilley
5UCB Pharma Raleigh NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Borghs
6UCB Pharma Slough United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc De Backer
8UCB Pharma SA Brussels Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyler Story
7UCB Pharma Smyrna GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Dedeken
4UCB Pharma Brussels Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Webster
5UCB Pharma Raleigh NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Comparative Cognitive Effects of Lacosamide versus Carbamazepine (P3.191)
David Loring, Kimford Meador, Alan Boyd, William Byrnes, Deanne Dilley, Simon Borghs, Marc De Backer, Tyler Story, Peter Dedeken, Elizabeth Webster
Neurology Apr 2015, 84 (14 Supplement) P3.191;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE:To evaluate cognitive and EEG effects of lacosamide (LCM) compared to carbamazepine immediate-release (CBZ-IR). BACKGROUND:Differential effectiveness of antiepileptic drugs (AEDs) is more commonly determined by tolerability than efficacy. Cognitive effects of AEDs can adversely affect tolerability and quality of life. DESIGN/METHODS:Randomized, double-blind, double-dummy, two-period crossover study (NCT01530022) in healthy controls comparing neuropsychological and EEG effects of LCM (150mg bid) and CBZ-IR (300mg bid, immediate release). Testing was conducted at screening, pre-drug baseline, end of each treatment period (3-week titration; 3-week maintenance), and end of each washout period (4 weeks after treatment). A composite Z-score was derived for the primary outcome variable (computerized cognitive tests and traditional neuropsychological paper/pencil measures, evaluating attention, speed, executive functions, and memory). Other variables included individual subcomponents of the composite score, EEG/EP measures, safety variables, and pharmacokinetic data. RESULTS: 60 healthy adults enrolled (57[percnt] female, mean age 34y [SD 10.5]); 44 completed both treatment periods. The primary analysis included 41 per protocol subjects. Wilcoxon rank sum test revealed worse effects for CBZ-IR compared to LCM for the primary cognitive outcome (0.33 [SD 1.36], p=0.01). Z-score differences compared to non-drug conditions were -0.26 for CBZ-IR and +0.08 for LCM. Secondary analyses of individual variables revealed CBZ-IR was statistically worse than LCM for 25[percnt] (4/16) of the neuropsychological variables and 20[percnt] (1/5) for EEG measures (i.e., P3 latency); none favored CBZ-IR. 22[percnt] of subjects receiving LCM and 49[percnt] receiving CBZ-IR had drug-related adverse events (AEs); 2 LCM and 8 CBZ-IR subjects discontinued due to AEs. CONCLUSIONS: LCM had fewer neuropsychological and EEG effects and fewer AEs and AE-related discontinuations than CBZ-IR in healthy subjects. Significant differences were observed for dual processing, psychomotor speed, perceived drug effects, and P3 latency. LCM exhibits a favorable cognitive profile compared to CBZ-IR. Study Supported by:UCB Pharma

Disclosure: Dr. Loring has received personal compensation for activities with NeuroPace as a consultant. Dr. Meador has received personal compensation for activities on behalf the Epilepsy Study Consortium with Eisai Inc., NeuroPace, Inc., Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma, and Vivus Pharmaceuticals as a consultant. Dr. Meador has rec Dr. Boyd has received personal compensation for activities with CNS Vital Signs as CEO. Dr. Byrnes has received personal compensation for activities with UCB Pharma as an employee. Dr. Dilley has received personal compensation for activities with UCB Pharma. Dr. Borghs has received personal compensation for activities with UCB Pharma as an employee. Dr. De Backer has received personal compensation for activities with UCB Pharma as an employee. Dr. Story has nothing to disclose. Dr. Dedeken has received personal compensation for activities with UCB Pharma as an employee. Dr. Webster has received personal compensation for activities with UCB Pharma as an employee. Dr. Webster holds stock and/or stock options in UCB Pharma.

Tuesday, April 21 2015, 2:00 pm-6:30 pm

  • Copyright © 2015 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise